产品说明书

(R)-Equol

Print
Chemical Structure| 221054-79-1 同义名 : R-雌马酚 ;Isoequol;(+)-Equol
CAS号 : 221054-79-1
货号 : A620368
分子式 : C15H14O3
纯度 : 99%
分子量 : 242.27
MDL号 : MFCD09025608
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(433.4 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 (R)-Equol is an agonist of ERα and ERβ with Ki of 27.4 nM and 15.4 nM, respectively[1].(R)-Equol dose-dependently inhibited the invasive capacity of MDA-MB-231 cells, with a significant effect at the highest concentration tested (50 μM). After 48 h of exposure to (R)-Equol, 50 μM (R)-Equol reduced the invasive capacity by 62%. The expression of MMP-2 was significantly down-regulated after treatment with 50 μM (R)-Equol[2].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01116310 Postmenopausal Women With Mode... 展开 >>rate Vasomotor Symptoms 收起 << Phase 4 Unknown July 2012 Spain ... 展开 >> Hospital Central de Asturias Withdrawn Asturias, Spain, H. Central de Asturias Hospital del Cruces Recruiting Barakaldo, Spain, 48903 Principal Investigator: José L. Neyro, Dr.          Assir CAP Sant Martí Withdrawn Barcelona, Spain, 08020 Hospital de la Santa Creu i Sant Pau Recruiting Barcelona, Spain, 08025 Principal Investigator: Misericordia Guinot, Dr.          USP Instituto Universitario Dexeus Active, not recruiting Barcelona, Spain, 08028 ASSIR CAP San Andreu Active, not recruiting Barcelona, Spain, 08030 Hospital Universitari Vall d'Hebrón Recruiting Barcelona, Spain, 08035 Principal Investigator: Francesc Baró, Dr.          Hospital Monteprincipe Recruiting Boadilla del Monte, Madrid, Spain, 28660 Principal Investigator: Manuel Marcos, Dr.          Hospital General de Ciudad Real Active, not recruiting Ciudad Real, Spain, 13005 Centro Diatros Recruiting Gavá (Barcelona), Spain, 08850 Principal Investigator: Rafael Sánchez Borrego, Dr.          Hospital Universitario de Guadalajara Recruiting Guadalajara, Spain, 19002 Principal Investigator: María J. Cancelo, Dr.          Consorci Sanitari d l´Anoia-H. de Igualada Recruiting Igualada, Barcelona, Spain, 08700 Principal Investigator: Ana R Pérez Aguado, Dr.          Centro de Estudios de Obstetricia y Ginecología Asociado Lugo Recruiting Lugo, Spain, 27002 Principal Investigator: Francisco Vázquez, Dr.          Gabinete Médico Velázquez Recruiting Madrid, Spain, 28001 Principal Investigator: Silvia González, Dr.          Instituto Palacios Recruiting Madrid, Spain, 28009 Principal Investigator: Santiago Palacios, Dr.          Hospital Mateu Orfila Withdrawn Mao, Spain, 07701 H. San Joan d'Alacant Recruiting San Juan, Alicante, Spain, 03550 Principal Investigator: Francisco Quereda, Dr.          Hospital Universitario La Fe Recruiting Valencia, Spain, 46009 Principal Investigator: Dolores Juliá, Dr.          Hospital Doctor Pesset Recruiting Valencia, Spain, 46017 Principal Investigator: Antonio Cano, Dr.          Hospital Miguel Servet Withdrawn Zaragoza, Spain, 50009 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.13mL

0.83mL

0.41mL

20.64mL

4.13mL

2.06mL

41.28mL

8.26mL

4.13mL
参考文献

[1]Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.

[2]Magee PJ, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2014 Feb;53(1):345-50.

[3]Brown NM, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis. 2010 May;31(5):886-93.